---
title: "Cox Proportional Hazards Model"
author: "Edwin Alvarado, Darnell Thomas, and Michael Ho"
format: revealjs
editor: visual
---

## Overview

-   What is the Cox Proportional Hazards Model?

-   Used to evaluate the association between survival time of a patient and one or more risk factors

-   Known for its ability to handle censored data

-   Can account for "realistic" outcomes of observations (i.e., the patient surviving)

## Defining the Statistical Model

The composition of the model is as follows:

$$ h_i(t) = h_0(t) \times exp(\beta_1X_{1i} + \beta_2X_{2i} + ... + \beta_kX_{ki}) $$

Where $H_0 (t)$ is considered to be the baseline hazard function of the model. $\beta_k$ are model parameters.

## The Hazard Ratio {.smaller}

Consider the following example:

$$ HR = {h_{pre}(t) \over h_{post}(t)} = {h_0(t)\times exp(0.0177 \times X_{pre}) \over h_0(t) \times exp(0.0177 \times X_{post})} $$ $$ = {exp(0.0177 \times 1) \over exp(0.0177 \times 0)} = 1.018$$ Similar to Odds Ratio in that:

-   HR \> 1 = Positive Effect
-   HR \< 1 = Negative Effect
-   HR = 1 = No Effect

## Applications and Limitations

-   Often used in medical field, e.g. clinical trials

-   While commonly used in medical research, can be applied to other fields, such as finance or social sciences

-   Originally form of the model, could not account for time-dependent variable effects

    -   Proportional Hazard Assumption

## Case Study: VA Lung Cancer Trial

Goals

-   Determine if treatment used in trial has positive effect on survival time
-   Determine if any other variables have significant effect on survival time
-   Properly test assumptions and fit the Cox Proportional Hazards Model

## Case Study: VA Lung Cancer Trial

::: panel-tabset
### Data Definition

```{r, echo=FALSE}
library(MASS)
library(kableExtra)
data(VA)
VA$status <- as.factor(VA$status)

a <- data.frame(vars = c('stime', 'status', 'treat', 'age', 'Karn', 'diag', 'cell', 'prior'),
               
                DataType = c('Numeric', 'Numeric', 'Nominal', 'Numeric', 'Numeric', 'Numeric','Nominal','Nominal'),
                Description = c('survival or follow-up time, in days',
    'dead or alive/censored; 0 (alive), 1 (dead)',
    'treatment, either standard or test (chemotherapy); 1 (standard), 2 (test)',
    'patient age in years',
    'Karnofsky score of patient performance, on scale of 0 to 100',
    'patient time since diagnosis, measured at time of entry to trial, in months',
    'one of four cell types; 1 (squamous), 2 (small cell), 3 (adeno), 4 (large)',
    'denotes prior therapy; 10 (yes), 0 (no)'),
                stringsAsFactors = FALSE)
 
kable(a,
      caption = "Table 1: Data Definition",
      col.names = c("Attribute", "Type", "Description"),
      align="lcl", escape = FALSE) %>%
  kable_styling(bootstrap_options = c("striped"), full_width = TRUE, font_size = 25) %>%
  row_spec(0, bold = T, background = "#666666", color = "white")
```

### Data Preview

```{r, echo=FALSE}
kable(head(VA, 6), caption = "Table 2: Sample Rows from VA Lung Trial Data") %>%
  kable_styling(bootstrap_options = c("striped", "hover"), full_width = TRUE, font_size = 25) %>%
  row_spec(0, bold = T, background = "#666666", color = "white")
```

### Initial Remarks

-   137 Observations of patients with inoperable lung cancer
-   Includes Censored Data
-   Per the National Cancer Institute, the Karnofsky score is standard way to measure how well a patient can perform ordinary tasks. A higher score indicates a higher ability to do these tasks
:::

## Summary Statistics {.tabset}

::: panel-tabset
### Numerical Variables

```{r, echo=FALSE}
summary_stats <- summary(VA[, c("stime", "age", "Karn", "diag.time")])
#Convert summary statistics to a table
kable(summary_stats, caption = "Table 3: Summary Statistics for VA Lung Trial Data") %>%
  kable_styling(bootstrap_options = c("striped", "hover"), full_width = TRUE, font_size = 25) %>%
  row_spec(0, bold = T, background = "#666666", color = "white")
```

### Categorical Variables

```{r}
#second prop summary
VA$status <- as.factor(VA$status)
summary_stats2 <- summary(VA[, c("status", "treat", "cell", "prior")])

#Convert summary statistics to a table
kable(summary_stats2, caption = "Table 4: Summary Count Statistics for VA Lung Trial Data") %>%
  kable_styling(bootstrap_options = c("striped", "hover"), full_width = TRUE) %>%
  row_spec(0, bold = T, background = "#666666", color = "white")
```
:::

## Data Visualization

::: panel-tabset
### Visualization

```{r}
#Create a scatter plot matrix using the GGally package
library(GGally)
library(tidyverse)
va_subset <- VA[, c("stime", "age", "Karn", "diag.time", "treat")]

ggpairs(va_subset, title = "Figure 1: Scatterplot Matrix of VA Lung Trial Data for Standard (Blue) and Test (Red)", 
        columns = c("stime", "age", "Karn", "diag.time"), ggplot2::aes(color = treat),
        lower = list(continuous = "points", combo = "dot_no_facet", mapping = ggplot2::aes(color=treat, alpha = 0.8)),
        diag = list(continuous = wrap("densityDiag"), mapping = ggplot2::aes(color = treat, alpha = 0.1))) +
  scale_color_manual(values = c("#00BFC4", "#F8766D"))
```

### Key Remarks

-   Distributions are roughly similar between standard and test treatment groups

-   Karnofsky and survival time seem positively correlated

### Code

```{r, eval = FALSE, echo = TRUE}
#Create a scatter plot matrix using the GGally package
library(GGally)
library(tidyverse)
va_subset <- VA[, c("stime", "age", "Karn", "diag.time", "treat")]

ggpairs(va_subset, title = "Figure 1: Scatterplot Matrix of VA Lung Trial Data for Standard (Blue) and Test (Red)", 
        columns = c("stime", "age", "Karn", "diag.time"), ggplot2::aes(color = treat),
        lower = list(continuous = "points", combo = "dot_no_facet", mapping = ggplot2::aes(color=treat, alpha = 0.8)),
        diag = list(continuous = wrap("densityDiag"), mapping = ggplot2::aes(color = treat, alpha = 0.1))) +
  scale_color_manual(values = c("#00BFC4", "#F8766D"))
```
:::

## Statistical Model

Recall the composition:

$$ h_i(t) = h_0(t) \times exp(\beta_1X_{1i} + \beta_2X_{2i} + ... + \beta_kX_{ki}) $$

## Model in R {.tabset}

Cox PH model for a single variable (treat)

::: panel-tabset
## Model Fit

```{r}
# Load Dataset
library(MASS)
data(VA)
```

```{r, echo=TRUE}
# Import packages
library(survival)

# Fit Cox PH Model for treatment only
Y = Surv(VA$stime, VA$status)
coxph(Y ~ treat, data=VA)
```

## Summary

```{r, echo=TRUE}
summary(coxph(Y ~ treat, data=VA))
```

## GT Summary

```{r, echo=TRUE}
library(gtsummary)
coxph(Y ~ treat, data=VA) %>% tbl_regression(exponentiate = T) %>% 
add_glance_table(include = c(logLik, concordance))
```
:::

## Proportional Hazard Assumption

-   The proportional hazard assumption is means that hazard ratio (HR) is constant over time.

-   Variables and regression coefficients are time-independent (no change over course of study).

-   Methods of checking PH assumption

    1.  Schoenfeld Residuals vs Time Plot

    2.  Statistical test of Schoenfeld Residuals

    3.  Log-Log Survival Curve

## 1. Residuals vs Time Plot

PH assumption is valid when coefficient is constant over time.

![](index_files/figure-html/unnamed-chunk-5-1.png){fig-alt="Plot of scaled Schoenfeld residuals and estimated beta versus time"}

## 2. Statistical Test

Test if Schoenfeld residuals are correlated with time. The null hypothesis $H_0$ is that the residuals are not correlated with time.

If p-value \< $\alpha$: 0.05, then PH assumption is violated.

```{r, echo=TRUE}
cox.zph(coxph(Y ~ treat, data=VA), transform = rank)
```

## 3. Survival Curves {.tabset}

::: panel-tabset
## Empirical

![Kaplan-Meier Survival Curve](index_files/figure-html/unnamed-chunk-7-1.png){width="800"}

## Log-Log

If log-log survival curves are parallel then the PH assumption is appropriate. **Since curves cross, PH assumption is violated.**

![](index_files/figure-html/unnamed-chunk-8-1.png){fig-align="center" width="600"}
:::

## Multiple Variable Cox Model {.tabset}

::: panel-tabset
## R Code

```{r, echo=TRUE}
coxph(Y ~ treat + age + Karn + diag.time + cell + prior, data=VA)
```

## PH Test

```{r, echo=TRUE}
cox.zph(coxph(Y ~ treat + age + Karn + diag.time + cell + prior, data=VA), transform=rank)
```

## Non-PH Plot

![](index_files/figure-html/unnamed-chunk-12-1.png){fig-alt="Schoenfeld plot of nonproportional variables" width="800"}
:::

## Options when PH assumption not met

1.  Subset data based time

    -   Start Cox PH model after certain time period (ie fit model for 180-day survivors)

    -   Doesn't consider individuals whose event occurred before 180 days

2.  Stratified Cox model

    -   Obtain separate models for each group (ie Cell Type)

    -   Cannot compare HR across stratified groups

## More Options when PH assumption not met

3.  Extended Cox model

    -   Specify function time-varying coefficients and/or time-dependent variables

    -   Could be harder to interpret depending on function

4.  Combination of 1, 2, or 3

## 1. Fitting Cox model for 180-day survivors

-   Only 27 individual left in study after 180 days.

-   Sample too small to make conclusions.

## 2. Stratified Cox model {.tabset}

::: panel-tabset
## Model

Assumes a different baseline hazard function for each Cell Type.

![](stratified%20cox%20model.png){fig-alt="Stratified cox model" width="1200"}

where $$g = 1, 2, 3, 4 \text{ (number of cell types)}$$

## Survival Curve

![](index_files/figure-html/unnamed-chunk-20-1.png){width="800"}

## R Code

```{r, echo=TRUE}
coxph(Y ~ treat + age + Karn + diag.time + strata(cell) + prior, data=VA)
```
:::

## 3. Extended Cox model {.tabset}

::: panel-tabset
## Time-Varying Coefficients

$$h_i(t)= h_0(t) \times exp(\beta_1(t)X_{1i} + ... + \beta_k(t)X_{ki}) $$Used to specify a function for the coefficients that change with time (linear, logarithmic, a step function, etc).

We used a step function for time intervals of 0-90, 90-180, and 180+ days.

## R Code Data

```{r, echo=TRUE}
#Creating tgroup column for each individual
VA.cp = survSplit(Surv(stime, status)  ~ ., data=VA, cut=c(90,180), episode="tgroup")

# Output first 7 entries
VA.cp[1:7, c("age","Karn","cell","tstart", "stime", "status", "tgroup")]
```

## R Code Model

```{r, echo=TRUE}
coxph(Surv(tstart, stime, status) ~ treat + age + diag.time + cell + prior + Karn:strata(tgroup),
                 data=VA.cp)
```
:::

## 4. Stratified-Extended (SE) Cox model

We can both stratify on cell type while using the extended model for the Karnofsky score.

```{r, echo=TRUE}
coxph(Surv(tstart, stime, status) ~ treat + age + diag.time + strata(cell) + prior + Karn:strata(tgroup),
                 data=VA.cp)
```

## Reducing Model {.tabset}

::: panel-tabset
## Likelihood Ratio Test

We can use the Log-Likelihood value ($L$) to determine if there is a significant difference in nested models.

$$\chi_{LR}^2 = -2\ln L_\text{reduced-model} - (-2\ln L_\text{full-model})$$

If $\chi_{LR}^2 > \chi_{df,\alpha}^2$ (ie p-value \< 0.05), then significant difference in models

## R Code

```{r}
cox.modse = coxph(Surv(tstart, stime, status) ~ treat + age + diag.time + strata(cell) + prior + Karn:strata(tgroup),
                 data=VA.cp)
cox.modse_r = coxph(Surv(tstart, stime, status) ~ treat + strata(cell) + Karn:strata(tgroup),
                 data=VA.cp)
```

```{r, echo=TRUE}
# Using anova with Likelihood ratio test
anova(cox.modse_r, cox.modse, test="LRT")
```
:::

## Final SE Cox model

Simplified the model to treat + Karn + cell.

![](stratified-extended%20cox%20model.png){fig-alt="Final stratified-extended cox model" width="1200" height="61"}

where $$g = 1, 2, 3, 4 \text{ (number of cell types)}$$ $$tgroup1 = 1 \text{ if  } 0 \le t < 90 $$ $$tgroup2 = 1 \text{ if  } 90 \le t < 180 $$ $$tgroup3 = 1 \text{ if  } t \ge 180$$

## SE Cox model Summary

```{r}
cox.modse_r %>% tbl_regression(exponentiate = T) %>% 
add_glance_table(
  include = c(logLik, concordance)
) %>%
  modify_caption("**Stratified-Extended Cox Model**")
```

## SE Cox model Interpretations {.tabset}

::: panel-tabset
### Treatment

-   Treatment effect was not found to be significant, with a p value of 0.6, in final Statified-Extended Cox model

### Karnofsky Score

-   Karnofsky's score was found to be significant but only in the first 90 days, with a p value \<0.001

-   In the first 90 days, for a 10-point decrease in Karnofsky score the probability of dying for a patient increase by 57%, all else constant

-   Karnofsky score is measured at the time of entry to the trial
:::

## Concluding Remarks

-   Cox Proportional Hazards Model is a useful tool in survival analysis

-   Regarding the case-study results...

-   It is due to the CPH's robust nature and being able to handle censored data, which leads it to be so          popular in survival analysis, as seen in our case-study
